AC Immune SA ACIU 深 沪
已收盘 12-12 16:00:00 美东时间
3.15
-0.070
-2.17%
华盛通- 最 高3.80
- 今 开3.43
- 成交量 270.75万股
- 最 低 3.12
- 昨 收 3.22
- 总市值 3.18亿
- 52周最高 4.00
- 市盈率 静 --
- 换手率 2.68%
- 52周最低 1.4299
- 委 比 79.41%
- 总股本 1.01亿
- 历史最高 17.40
- 量 比 0.64
- 振 幅 21.12%
- 历史最低 1.4299
- 每 手 1
- 风险率 0.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股牛股 | SMX飙升45%，公司在棉花可追溯性方面获重大突破；PL大涨35%
SMX飙升45%，公司在棉花可追溯性方面获重大突破；PL大涨35%，财报收入大增超预期；GEMI大涨32%，公司获合约市场牌照进军预测市场>>
12-12 16:17
AC Immune Announces Interim Safety And Efficacy Results From Phase 2 VacSYn Trial Of Its Wholly-Owned Anti-Alpha-Synuclein Active Immunotherapy ACI-7104.056 In Early Parkinson's Disease
AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced positive interim safety and efficacy results from the Phase 2
12-11 20:02
AC Immune to Present at the Jefferies 2025 London Healthcare Conference
AC Immune will participate in the Jefferies 2025 London Healthcare Conference on November 17-20, 2025. Company management will engage in a fireside chat on November 18 at 4:30 AM ET/9:30 AM GMT, available via webcast on AC Immune’s Events Page, with a replay later. AC Immune, a clinical-stage biopharma leader in precision therapeutics for neurodegenerative diseases, employs SupraAntigen® and Morphomer® platforms to develop therapeutic and diagnos...
11-11 12:00
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
11-05 10:35
BTIG Reiterates Buy on AC Immune, Maintains $8 Price Target
BTIG analyst Thomas Shrader reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $8 price target.
11-05 01:02
AC Immune Q3 EPS $(0.20) Beats $(0.22) Estimate, Sales $1.174M Miss $1.520M Estimate
AC Immune (NASDAQ:ACIU) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.22) by 9.09 percent. This is a 433.33 percent decrease over earnings of $0.06 per share from the
11-04 20:19
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
AC Immune announced its Q3 2025 financial results with a sharpened focus on high-value assets including three Phase 2 active immunotherapy programs and small molecule programs targeting NLRP3, Tau, and a-syn. The company reported CHF 108.5 million in cash resources, providing funding until Q3 2027. Key achievements include groundbreaking research published in peer-reviewed journals and the expected filing of IND/CTA for ACI-19764 and Morphomer-Ta...
11-04 12:00
AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board
AC Immune appoints Catherine Mummery as Chair of its Clinical Advisory Board (CAB). Prof. Mummery, a leading neurologist specializing in dementia trials, brings extensive expertise in developing innovative therapies targeting neurodegenerative diseases. She has led numerous early-stage trials, including AC Immune's anti-pTau immunotherapy ACI-35.030. Mummery's appointment strengthens AC Immune's pipeline of precision prevention candidates, includ...
10-28 11:00
AC Immune's Preclinical Data On Brain Positron Emission Tomography Tracers For Imaging Tdp-43 Pathology ACI-19626 Candidate Demonstrates High Specificity, Selectivity For Target
AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced the publication in Nature Communications of preclinical data on its
10-24 20:55
First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine
AC Immune's ACI-19626, a novel TDP-43 PET tracer, has been characterized in *Nature Communications* and shows promise for precision medicine in neurodegenerative diseases like ALS, FTD, and LATE. TDP-43 aggregates are a key pathological marker in these conditions, complicating diagnosis. ACI-19626 demonstrates high specificity and sensitivity for detecting TDP-43 pathology, with favorable pharmacokinetic properties for brain PET imaging. The trac...
10-24 12:50
